592 related articles for article (PubMed ID: 27879277)
1. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species.
Liu RR; Lv YS; Tang YX; Wang YF; Chen XL; Zheng XX; Xie SZ; Cai Y; Yu J; Zhang XN
Oncotarget; 2016 Apr; 7(17):24348-60. PubMed ID: 27028999
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
5. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis.
Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D
Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM
Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA GAS6-AS1 acts as a ceRNA for microRNA-585, thereby increasing
Ai J; Sun J; Zhou G; Zhu T; Jing L
Cell Cycle; 2020 Apr; 19(7):742-757. PubMed ID: 32089066
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of microRNA-9 enhances cisplatin sensitivity in hepatocellular carcinoma by regulating EIF5A2-mediated epithelial-mesenchymal transition.
Bao Y; Zhang Y; Lu Y; Guo H; Dong Z; Chen Q; Zhang X; Shen W; Chen W; Wang X
Int J Biol Sci; 2020; 16(5):827-837. PubMed ID: 32071552
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY
Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253
[TBL] [Abstract][Full Text] [Related]
10. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.
Tang DJ; Dong SS; Ma NF; Xie D; Chen L; Fu L; Lau SH; Li Y; Li Y; Guan XY
Hepatology; 2010 Apr; 51(4):1255-63. PubMed ID: 20112425
[TBL] [Abstract][Full Text] [Related]
12. Ablation of EIF5A2 induces tumor vasculature remodeling and improves tumor response to chemotherapy via regulation of matrix metalloproteinase 2 expression.
Wang FW; Cai MY; Mai SJ; Chen JW; Bai HY; Li Y; Liao YJ; Li CP; Tian XP; Kung HF; Guan XY; Xie D
Oncotarget; 2014 Aug; 5(16):6716-33. PubMed ID: 25071013
[TBL] [Abstract][Full Text] [Related]
13. RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma.
Shang R; Wang J; Sun W; Dai B; Ruan B; Zhang Z; Yang X; Gao Y; Qu S; Lv X; Tao K; Wang L; Dou K; Wang D
Tumour Biol; 2016 Apr; 37(4):5097-105. PubMed ID: 26546438
[TBL] [Abstract][Full Text] [Related]
14. Sonic Hedgehog-GLI Family Zinc Finger 1 Signaling Pathway Promotes the Growth and Migration of Pancreatic Cancer Cells by Regulating the Transcription of Eukaryotic Translation Initiation Factor 5A2.
Xu X; Liu H; Zhang H; Dai W; Guo C; Xie C; Wei S; He S; Xu X
Pancreas; 2015 Nov; 44(8):1252-8. PubMed ID: 26465952
[TBL] [Abstract][Full Text] [Related]
15. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) correlates with cell aggressiveness and poor survival in gastric cancer.
Meng QB; Kang WM; Yu JC; Liu YQ; Ma ZQ; Zhou L; Cui QC; Zhou WX
PLoS One; 2015; 10(3):e0119229. PubMed ID: 25793713
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition.
Zhu W; Cai MY; Tong ZT; Dong SS; Mai SJ; Liao YJ; Bian XW; Lin MC; Kung HF; Zeng YX; Guan XY; Xie D
Gut; 2012 Apr; 61(4):562-75. PubMed ID: 21813470
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer.
Zhang H; Zhang K; Ning L; Chen D; Hao F; Li P
Bioengineered; 2020 Dec; 11(1):1325-1333. PubMed ID: 33200656
[TBL] [Abstract][Full Text] [Related]
20. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]